This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05123/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05123/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05123/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05123/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05123
rdf:type
n3:Drug
n3:description
Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
n3:generalReferences
# Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D: Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16353929 # Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE: Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003 Sep 1;92(5):538-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12943873
n3:group
investigational
n3:indication
Investigated for use/treatment in atherosclerosis, cardiovascular disorders, and hyperlipidemia.
owl:sameAs
n7:DB05123
dcterms:title
Gemcabene
adms:identifier
n9:157692 n10:10253171 n11:138760 n12:DB05123
n3:IUPAC-Name
n4:271B6448-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B644E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B644D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B644A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B644B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B644C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6446-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6447-363D-11E5-9242-09173F13E4C5 n4:271B6444-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6445-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6454-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6455-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B644F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6450-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6452-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6451-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6453-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
183293-82-5
n3:Bioavailability
n4:271B645A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B645C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B645D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6459-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6458-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B645B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6449-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6456-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6457-363D-11E5-9242-09173F13E4C5